Autor segons l'article: Lopez, Carlos; Bosch, Ramon; Korzynska, Anna; Garcia-Rojo, Marcial; Bueno, Gloria; Francesc Garcia-Fontgivell, Joan; Martinez Gonzalez, Salome; Gras Navarro, Andrea; Sauras Colon, Esther; Casanova Ribes, Julia; Roszkowiak, Lukasz; Mata, Daniel; Arenas, Meritxell; Gomez, Junior; Roso, Albert; Berenguer, Marta; Reverte-Villarroya, Silvia; Llobera, Montserrat; Baucells, Jordi; Lejeune, Marylene
Departament: Ciències Mèdiques Bàsiques Infermeria
Autor/s de la URV: Arenas Prat, Meritxell / BAUCELLS LLADÓS, JOAN / Berenguer Poblet, Marta / Bosch Príncep, Ramon / Gómez Alvarez, Josep / Gras Navarro, Andrea / Lejeune, Marylène Marie / Lopez Pablo, Carlos / Martínez González, María Salomé / REVERTÉ REVERTÉ, SANDRA / Reverté Villarroya, Silvia / Sauras Colón, Esther
Paraules clau: Triple negative breast neoplasms Survival Prognosis Outcome Neoplasm recurrence, local Lymph nodes Immune markers Humans Female Dendritic cells Breast neoplasms Breast cancer Axillary lymph nodes (alns) Axilla t-cells survival outcome metastasis lymphocytes immune markers expression axillary lymph nodes (alns)
Resum: The foremost cause of death of breast cancer (BC) patients is metastasis, and the first site to which BC predominantly metastasizes is the axillary lymph node (ALN). Thus, ALN status is a key prognostic indicator at diagnosis. The immune system has an essential role in cancer progression and dissemination, so its evaluation in ALNs could have significant applications. In the present study we aimed to investigate the association of clinical-pathological and immune variables in the primary tumour and non-metastatic ALNs (ALNs-) of a cohort of luminal A and triple-negative BC (TNBC) patients with cancer-specific survival (CSS) and time to progression (TTP).We analysed the differences in the variables between patients with different outcomes, created univariate and multivariate Cox regression models, validated them by bootstrapping and multiple imputation of missing data techniques, and used Kaplan-Meier survival curves for a 10-years follow-up.We found some clinical-pathological variables at diagnosis (tumour diameter, TNBC molecular profile and presence of ALN metastasis), and the levels of several immune markers in the two studied sites, to be associated with worse CSS and TTP. Nevertheless, only CD68 and CD83 in ALNs- were confirmed as independent prognostic factors for TTP.The study identified the importance of macrophage and dendritic cell markers as prognostic factors of relapse for BC. We highlight the importance of studying the immune response in ALNs-, which could be relevant to the prediction of BC patients' outcome.© 2022. The Author(s), under exclusive licence to The Japanese Breast Cancer Society.
Àrees temàtiques: Radiology, nuclear medicine and imaging Pharmacology (medical) Oncology Obstetrics & gynecology Medicine (miscellaneous) Medicina i
Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
Adreça de correu electrònic de l'autor: ramon.bosch@urv.cat josep.gomez@urv.cat carlos.lopez@urv.cat mariasalome.martinez@urv.cat silvia.reverte@urv.cat marylenemarie.lejeune@urv.cat esther.sauras@estudiants.urv.cat ramon.bosch@urv.cat meritxell.arenas@urv.cat marta.berenguer@urv.cat
Identificador de l'autor: 0000-0002-0573-7621 0000-0003-1248-3065 0000-0001-6185-2889 0000-0002-2052-9978 0000-0001-8441-9404 0000-0003-0815-2570 0000-0002-6631-3777
Data d'alta del registre: 2024-09-28
Versió de l'article dipositat: info:eu-repo/semantics/acceptedVersion
Enllaç font original: https://link.springer.com/article/10.1007/s12282-022-01336-2
URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
Referència a l'article segons font original: Breast Cancer. 29 (4): 618-635
Referència de l'ítem segons les normes APA: Lopez, Carlos; Bosch, Ramon; Korzynska, Anna; Garcia-Rojo, Marcial; Bueno, Gloria; Francesc Garcia-Fontgivell, Joan; Martinez Gonzalez, Salome; Gras N (2022). CD68 and CD83 immune populations in non-metastatic axillary lymph nodes are of prognostic value for the survival and relapse of breast cancer patients. Breast Cancer, 29(4), 618-635. DOI: 10.1007/s12282-022-01336-2
DOI de l'article: 10.1007/s12282-022-01336-2
Entitat: Universitat Rovira i Virgili
Any de publicació de la revista: 2022
Tipus de publicació: Journal Publications
Repositori URV